Oncologist shares details of cancer vaccine clinical trials

Men and women aged 18 to 75 with a confirmed diagnosis will be able to participate in clinical trials of the oncovaccine being developed in Russia. This statement was made on December 14 by oncologist and general director of the NMIC of Radiology Andrei Kaprin.

"The study will be conducted on the basis of the NMIC of Radiology of the Ministry of Health and is aimed at studying the safety, tolerability, pharmacokinetics of the drug created on the basis of enteroviruses," - said Kaprin in his Telegram-channel.

He also stressed that only people with a histologically confirmed diagnosis of "solid inoperable tumor", for whom standard treatment options are no longer possible, will be allowed to participate in the study. The oncologist noted that the general health of the candidates should be assessed on the ECOG scale between 0-2.

The domestic vaccine was developed at the NMRC of Radiology of the Ministry of Health of Russia in cooperation with the Engelhardt IMB of the Russian Academy of Sciences and was named "EnteroMix".

Spot-on: melanoma vaccine to be tested on patients in fall 2025

What is the principle of its work and how promising is the personalized approach

Earlier, on December 14, Andrey Kaprin reported that the cancer vaccine will be free for all Russian citizens. In addition, he said that the vaccine received high efficiency in preclinical tests.

Before that, on November 25, Russian President Vladimir Putin called the introduction of a vaccine against cancer a breakthrough. Then, at a meeting with the head of state, the head of the Federal Medical and Biological Agency (FMBA) Veronika Skvortsova told him about the agency's innovative developments in the field of biotechnology, including oncovaccines. Skvortsova noted that it will take about a year to test all components separately and together, and after all these tests, the Russian personalized cancer vaccine will start to be used.